RUBICON Share Price | Rubicon Research Ltd Stock Analysis & Recommendation

Q: When is the next results date for Rubicon Research Ltd?

The next results date for Rubicon Research Ltd is scheduled for 03 February 2026.

Q: Should I buy, sell or hold Rubicon Research Ltd?

Based on the information available, Rubicon Research Ltd appears to be a strong candidate for a buy. The company has demonstrated solid long-term fundamental strength, with a healthy ability to service its debt, indicated by a low Debt to EBITDA ratio of 0.78 times. Additionally, the significant growth in net profit of 88.33% and strong operating profit metrics suggest robust performance.However, it's important to consider the risks as well. The company's return on equity (ROE) is 19.1, which indicates a very expensive valuation with a Price to Book Value of 16.8. This could suggest that the stock may be overvalued relative to its earnings potential.In summary, if you are comfortable with the valuation risk and believe in the company's growth trajectory, it may be a good time to buy. Otherwise, you might consider holding or selling if you are concerned about the high valuation.

Q: Why is Rubicon Research Ltd falling/rising?

As of 02-Jun, Rubicon Research Ltd's stock price is rising, currently at 1,314.40, reflecting a change of 147.35 or 12.63% increase. This upward movement is supported by several factors. The stock has shown significant performance over the past week, with a rise of 34.48%, while the benchmark Sensex has decreased by 1.79%. Over the past month, the stock has increased by 35.46%, contrasting with a 2.94% decline in the Sensex.Today, the stock reached a new 52-week and all-time high of Rs 1,371.75, marking a 17.54% increase at its intraday peak. It has been gaining consistently for the last three days, accumulating returns of 36.09% during this period. The stock opened with a gain of 4.11% today, indicating strong investor interest. Additionally, the stock has been highly volatile, with an intraday volatility of 7.57%, which suggests active trading.Investor participation has also increased, with delivery volume rising by 510.85% against the 5-day average, indicating heightened interest from investors. Furthermore, Rubicon Research is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish signal.The company's strong financial performance, highlighted by an 88.33% growth in net profit and robust operating profit metrics, further supports the stock's rise. Despite a high valuation indicated by a Price to Book Value of 16.8, the strong fundamentals and positive market sentiment are driving the stock price upward.

Results Declared: Rubicon Research has declared results on 30 May 2026! Click here to unlock the latest financial performance

Technical Trend Update: Rubicon Research witnessed a change in Technical Grade on 02 Jun 2026. Click here to discover latest technical change!

Mojo Score Change: Rubicon Research has changed its score on 01 Jun 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

20.15 lacs (-33.22%) Volume

Shareholding (Mar 2026)

FII

7.54%

Held by 28 FIIs

DII

10.02%

Held by 11 DIIs

Promoter

59.86%

When is the next results date for Rubicon Research Ltd?

28-Jan-2026

The next results date for Rubicon Research Ltd is 03 February 2026.

View full answer

Should I buy, sell or hold Rubicon Research Ltd?

03-Jun-2026

Why is Rubicon Research Ltd falling/rising?

03-Jun-2026

As of 02-Jun, Rubicon Research Ltd's stock price is rising to 1,314.40, reflecting a 12.63% increase. The stock has shown significant gains recently, reaching a new all-time high and benefiting from strong investor interest and solid financial performance.

View full answer

Which are the latest news on Rubicon Research?

03-Jun-2026

Rubicon Research Ltd Surges on Bullish Technical Momentum and Strong Market Returns
Rubicon Research Ltd Surges 9.95% to Day's High of Rs 1285.7 — Outperforms Sector by 10.56 Percentage Points

Compare Rubicon Research with Similar Stocks

Neuland Labs.OneSource Speci.Astrazeneca Phar

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Healthy long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at 0%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times

With a growth in Net Profit of 88.33%, the company declared Outstanding results in Mar 26

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 20,981 Cr (Small Cap)

P/E

84.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

19.14%

Price to Book

16.80

Revenue and Profits:

Net Sales:

514 Cr

(Quarterly Results - Mar 2026)

Net Profit:

77 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

65.42%

6 Months

101.62%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Rubicon Research for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Rubicon Research Ltd Surges on Bullish Technical Momentum and Strong Market Returns

Rubicon Research Ltd has demonstrated a remarkable price momentum shift, supported by a strong technical upgrade and a significant surge in market performance. The pharmaceutical and biotechnology small-cap stock has been re-rated to a Strong Buy with a Mojo Score of 90.0, reflecting robust bullish signals across multiple technical indicators and a substantial outperformance relative to the Sensex.

Read full news article

Rubicon Research Ltd Surges 9.95% to Day's High of Rs 1285.7 — Outperforms Sector by 10.56 Percentage Points

The Sensex gained a modest 0.75% on 2 Jun 2026, while Rubicon Research Ltd surged 9.95%, outperforming its Pharmaceuticals & Biotechnology sector by 10.56 percentage points. This sharp single-session advance, which pushed the stock to a new 52-week and all-time high of Rs 1285.7, signals a strong momentum continuation rather than a mere technical bounce.

Read full news article

Rubicon Research Ltd is Rated Strong Buy

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 02 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

02-Jun-2026 | Source : BSE

Earning Call Transcript

Earnings Call Audio Recording

30-May-2026 | Source : BSE

Earnings Call Audio Recording

Announcement under Regulation 30 (LODR)-Newspaper Publication

30-May-2026 | Source : BSE

Rubicon Newspaper Publication under reg 30

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

6.10

Debt to EBITDA (avg)

1.50

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.16

Tax Ratio

23.02%

Dividend Payout Ratio

0.23%

Pledged Shares

Institutional Holding

17.55%

ROCE (avg)

25.58%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

15.99

EV to EBIT

57.96

EV to EBITDA

51.41

EV to Capital Employed

16.41

EV to Sales

11.73

PEG Ratio

Dividend Yield

ROCE (Latest)

28.31%

ROE (Latest)

19.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

KST

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 12 Schemes (7.14%)

FIIs

Held by 28 FIIs (7.54%)

Promoter with highest holding

General Atlantic Singapore Rr Pte Ltd (35.89%)

Highest Public shareholder

Shivanand Shankar Mankekar Huf (13.54%)

Individual Investors Holdings

2.82%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "389.88",
          "val2": "301.71",
          "chgp": "29.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "106.17",
          "val2": "62.24",
          "chgp": "70.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "7.51",
          "chgp": "-28.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "70.02",
          "val2": "37.18",
          "chgp": "88.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.23%",
          "val2": "20.63%",
          "chgp": "6.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "614.49",
          "val2": "528.16",
          "chgp": "16.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142.24",
          "val2": "144.68",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.06",
          "val2": "16.26",
          "chgp": "11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "80.96",
          "val2": "89.04",
          "chgp": "-9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.15%",
          "val2": "27.39%",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "916.20",
          "val2": "773.03",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "204.48",
          "val2": "208.58",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.57",
          "val2": "23.51",
          "chgp": "8.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "118.14",
          "val2": "127.27",
          "chgp": "-7.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "26.98%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,753.96",
          "val2": "1,284.27",
          "chgp": "36.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "400.24",
          "val2": "264.26",
          "chgp": "51.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "42.17",
          "val2": "36.78",
          "chgp": "14.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "246.74",
          "val2": "134.36",
          "chgp": "83.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.82%",
          "val2": "20.58%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

389.88

301.71

29.22%

Operating Profit (PBDIT) excl Other Income

106.17

62.24

70.58%

Interest

5.40

7.51

-28.10%

Exceptional Items

0.00

Standalone Net Profit

70.02

37.18

88.33%

Operating Profit Margin (Excl OI)

27.23%

20.63%

6.60%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

614.49

528.16

16.35%

Operating Profit (PBDIT) excl Other Income

142.24

144.68

-1.69%

Interest

18.06

16.26

11.07%

Exceptional Items

0.00

Standalone Net Profit

80.96

89.04

-9.07%

Operating Profit Margin (Excl OI)

23.15%

27.39%

-4.24%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

916.20

773.03

18.52%

Operating Profit (PBDIT) excl Other Income

204.48

208.58

-1.97%

Interest

25.57

23.51

8.76%

Exceptional Items

0.00

Standalone Net Profit

118.14

127.27

-7.17%

Operating Profit Margin (Excl OI)

22.32%

26.98%

-4.66%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

1,753.96

1,284.27

36.57%

Operating Profit (PBDIT) excl Other Income

400.24

264.26

51.46%

Interest

42.17

36.78

14.65%

Exceptional Items

0.00

Consolidate Net Profit

246.74

134.36

83.64%

Operating Profit Margin (Excl OI)

22.82%

20.58%

2.24%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025

All Annual Results

Company CV

About Rubicon Research Ltd

Rubicon Research Ltd

Small Cap

Pharmaceuticals & Biotechnology

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.

Company Coordinates

No Company Details Available